RNAImmune

3 articles with RNAImmune

• 

  Money on the Move: March 23-29 

  3/30/2022

  This week, money moved in the form of equity financing, upfront partnership payments, nonprofit donations and federal funding. 

• RNAimmune Secures $27 Million Series A Round of Financing for Development of mRNA Therapeutics and Vaccines

  3/29/2022

   RNAimmune, Inc. (the "Company" or "RNAimmune"), a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, announced today that is has secured an approximately US$27 million Series A round of financing.

• Sirnaomics' Spin-Off RNAimmune Secures $10 Million Seed Financing to Advance its mRNA-Based Vaccine and Therapeutic Development

  4/21/2021

  RNAimmune, Inc., a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, announced today execution of definitive agreements for a seed round financing of $10 million